|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 503 active entries
8755 Ash Street, Suite 1
Vancouver, BC V6P 6T3
Toll free: 1-866-KINEXUS
General Company Profile
Kinexus is a signal transduction company that utilizes innovative strategies to map and exploit intracellular communication systems involving protein kinases for drug discovery and development. Kinexus has developed proprietary methodologies and services for profiling hundreds of cell signalling proteins simultaneously to identify and validate disease markers, drug targets and leads. Kinexus provides clients and partners with access to its unique capabilities and knowledge through custom and collaborative research projects.
Kinexus provides a systems biology approach to solving problems relating to cell signalling and drug discovery. Kinexus currently offers products including high quality antibody micorarrays, peptides, peptide arrays and antibodies, as well as services relating to signal transduction. The services include antibody microarrays, peptide arrays, kinase profiling, substrate profiling, mass spectrometry, bioinformatics analysis and standard screens that track the expression levels and phosphorylation states of hundreds of known cell signalling proteins within thematic families of protein kinases, phosphatases, stress/heat shock, cell cycle and apoptosis proteins. Kinexus is developing second-generation high-throughput screening methods to improve the speed, sensitivity, breadth and cost of its proteomics services and also provides customized solutions to clients.
Kinexus proteomics services provide significant cash flow, and unique data acquisition opportunities. Kinexus leverages its knowledge and capabilities to establish larger scale outsourcing opportunities and corporate alliances. Kinexus plans to collaborate with industry leaders to develop its clinically validated drug targets.
Kinexus has established service-based relationships with thousands of clients including leading international pharmaceutical companies, prominent academic research institutions and government agencies. Kinexus is interested in forging collaborate research projects, partnership opportunities and corporate alliances in which Kinexus can supply promising drug targets, leads and additional information to improve drug development.
The existing platform technology is used evaluate drug leads, the suitability of animal models of human disease, and generating new drug targets that could be exploited or licensed. Kinexus has demonstrated that its antibody-based Kinetworks™ screening platform can identify novel cross-reactive proteins, which has led to the identification of potential drug targets for which patents have been filed. Furthermore Kinexus has begun to identify novel disease markers.
Last update of this entry: July 16, 2020